Dietary remodeling of intestinal microbiota to reduce the number of cardiovascular events in patients after acute myocardial infarction

Dietary remodeling of intestinal microbiota to reduce the number of cardiovascular events in patients after acute myocardial infarction

IRN AP 09259661


Proven baseline: trimethylamine-N-oxide (TMAO) - a metabolite of the gut microbiota associated with cardiovascular events, and the level of TMOA reflects the risk of atherothrombosis and thromboembolism. Evidence hypothesis: dietary intervention (metabiotic and grape polyphenol concentrate) at the microbiome level to reduce TMAO levels will reduce the number of future cardiovascular events in patients after acute ST-segment elevation myocardial infarction (STEMI).


To prove the possibility of reducing the number of cardiovascular events in patients after acute myocardial infarction during dietary remodeling of the intestinal microbiota with reference to the level of TMAO. Evidence is expected to come from a randomized controlled clinical trial.

Expected results

Achieving the goal of the project involves the following stages:

  1. Prepare documents for clinical research (Protocol, Brochure, Informed Consent), obtain approval from the Ethics Committee.
  2. Conduct screening and form a study cohort of patients after percutaneous coronary stenting for STEMI and randomize 1: 1 into the following groups: control group without intervention in the microbiome; group correction of the microbiome with metabiotic and grape polyphenol concentrate.
  3. Carry out dietary intervention for 3 months in the following groups: 1. control group on a habitual diet in accordance with the recommendations of cardiologists for secondary prevention after STEMI; Group 2 - a habitual diet with the addition of a daily intake of a metabiotic by 1 capsule and a 15 ml grape polyphenol concentrate (1 tablespoon).
  4. Determine the level of TMAO and the level of oxidative stress in patients in the acute phase of STEMI and in the chronic phase (after 10 months) after microbiome correction.
  5. Determine the structure of the intestinal microbiome in the acute and chronic phases of STEMI (after 10 months).
  6. To analyze the frequency of cardiovascular events (myocardial infarction, stroke) in patients after STEMI in the compared groups within 12 months.
  7. Assess the risk of atherothrombosis in patients using the SYNTAX calculator in the acute phase and chronic phase (after 10 months), determine in ΔSYNTAX points in each study group.

Achieved Results

  1. Documents for conducting a clinical trial have been prepared: Clinical Protocol, Investigator's Brochure, Informed Consent, Information and Registration Card, Material for informing research subjects and other auxiliary materials.
  2. Screening for the formation of the study cohort of study subjects has begun. The recruiting of patients in the acute period of myocardial infarction has begun. Recruiting patients with ST-segment elevation acute myocardial infarction after percutaneous coronary intervention.

First and last names of members of the research group with their identifiers (Scopus Author ID, Researcher ID, ORCID etc.) and links to the relevant profiles:

Zhumadilov Zhaxybay, PhD, prof.

Author ID in Scopus 12546177700 (

Researcher ID Web of Science D-8117-2012 (

ORCID ID 0000-0003-3855-6429 (

Researcher ID in Publons D-8117-2012


Gulyayev Alexander, Doctor of medical science, Prof.

Author ID at Scopus 57188714393 (

Researcher ID Web of Science AAR-7030-2020 (

ORCID ID 0000-0001-5098-4675 (

Researcher ID in Publons AAR-7030-2020

Sergazy Shynggys, PhD

Author ID at Scopus 57053283300 (

Researcher ID Web of Science AAR-6438-2020 (

ORCID ID 0000-0002-6030-620X (

Researcher ID in Publons AAR-6438-2020